Acceleron Pharma was officially acquired by Merck and Company, a major global healthcare and pharmaceutical leader, in a definitive all-cash transaction valued at approximately $11.5 billion. The strategic acquisition brought Acceleron's entire pipeline under Merck's corporate umbrella, allowing the pharmaceutical giant to expand its footprint into rare diseases and strengthen its long-term cardiovascular portfolio. Following customary regulatory clearances and overwhelming approval from shareholders, the multi-billion-dollar transaction was successfully finalized, integrating Acceleron as a wholly-owned subsidiary.